ABIONYX Pharma Announces Its Financial Agenda for the Year 2021
25 Janvier 2021 - 08:00AM
Business Wire
Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA
PME eligible), a new generation biotech company dedicated to
the discovery and development of innovative therapies for patients,
today announces its financial agenda for 2021.
Events
Date*
Cash position and activity update for
Q4 2020
February 4, 2021
2020 Annual Results
February 25, 2021
Cash position and activity update for
Q1 2021
May 6, 2021
Cash position and activity update for
Q2 2021
August 5, 2021
2021 Half Year Results
September 9, 2021
Cash position and activity update for
Q3 2021
November 4, 2021
* indicative dates subject to change
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company dedicated to
the discovery and development of innovative therapies for patients.
The biotech assets inherited from CERENIS Therapeutics constitute a
rich portfolio of valuable programs for the treatment of metabolic
diseases as well as with a HDL targeted drug delivery platform.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210124005045/en/
NewCap Investor relations Louis-Victor Delouvrier
abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Nicolas Merigeau abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024